M&A / Deals Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic Pharmaceutical TechnologyThe funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.M&A / DealsOncologyRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) Pharmaceutical Technology The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic. M&A / DealsOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Activist investor renews its criticism of NovavaxNext: Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment Update Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
